Empagliflozin 864070-44-0: A Comprehensive Guide to its Properties, Applications, and Benefits
Discover the key insights into Empagliflozin, a vital compound for diabetes and heart failure management.
Get a Quote & SampleProduct Core Value
Empagliflozin
Empagliflozin is a highly effective SGLT-2 inhibitor that plays a crucial role in managing type 2 diabetes and improving cardiovascular and renal outcomes. Its mechanism of action involves increasing urinary glucose excretion, thereby lowering blood sugar levels. Beyond glycemic control, it demonstrates significant benefits in reducing the risk of cardiovascular death and hospitalizations in patients with heart failure, and also in slowing the progression of chronic kidney disease.
- Explore the extensive empagliflozin uses in managing type 2 diabetes by enhancing glucose excretion via the kidneys.
- Understand the critical empagliflozin side effects and precautions to ensure safe and effective patient care.
- Delve into the detailed empagliflozin mechanism of action, explaining its role as an SGLT-2 inhibitor and its broader physiological impacts.
- Review the findings from numerous empagliflozin clinical trials that highlight its efficacy in various patient populations, including those with cardiovascular disease and heart failure.
Key Advantages
Improved Glycemic Control
Empagliflozin effectively lowers blood sugar levels in adults with type 2 diabetes, acting independently of insulin secretion or sensitivity, making it a valuable therapeutic option. This contributes to better overall diabetes management.
Cardiovascular Protection
Extensive empagliflozin cardiovascular benefits have been demonstrated, showing a significant reduction in the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.
Heart Failure Management
The compound offers substantial benefits for patients with heart failure, reducing the risk of hospitalization and cardiovascular death, as supported by robust empagliflozin for heart failure studies.
Renal Health Support
Empagliflozin's role in empagliflozin kidney protection is significant, as it has shown to slow the progression of chronic kidney disease and reduce the risk of end-stage kidney disease.
Key Applications
Type 2 Diabetes Management
As an adjunct to diet and exercise, Empagliflozin is a cornerstone in improving glycemic control for adults and adolescents with type 2 diabetes, offering a distinct mechanism of action compared to other antidiabetic agents.
Cardiovascular Risk Reduction
For adults with type 2 diabetes and established cardiovascular disease, Empagliflozin significantly reduces the risk of cardiovascular death, offering a dual benefit for patients.
Heart Failure Treatment
Empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, showcasing its cardioprotective properties.
Chronic Kidney Disease Support
The compound demonstrates efficacy in reducing the risk of kidney disease progression and related adverse outcomes in adults with chronic kidney disease, highlighting its nephroprotective effects.